Antithrombotic Effects of Recombinant Human, Active Site–Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis
- 23 January 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 82 (1) , 39-46
- https://doi.org/10.1161/01.res.82.1.39
Abstract
—The extrinsic coagulation pathway is activated when circulating factor VII (FVII) gains access to tissue factor (TF) exposed as a consequence of vascular injury. Increasing evidence indicates that this TF-dependent activation of the coagulation plays an important role in the pathophysiology of intravascular thrombus formation. In the present study, we tested the effects of recombinant human, active site–blocked activated FVII (FVIIai) in a rabbit model of carotid artery thrombosis. Cyclic flow variations (CFVs), due to recurrent thrombus formation, were obtained in stenotic rabbit carotid arteries with endothelial injury. Carotid blood flow velocity was measured by a Doppler flow probe. After 30 minutes of CFVs, the animals received FVIIai (100 μg · kg−1 · min−1 intracarotid infusion for 10 minutes, n=9). If CFVs were abolished, animals were followed for 30 additional minutes, after which recombinant human activated FVII (FVIIa) was infused into the carotid artery (100 μg · kg−1 · min−1 for 10 minutes) to determine whether FVIIai could be displaced from TF by FVIIa, thus restoring CFVs. To establish the duration of action of FVIIai, an additional group of animals received FVIIai at the same dose as above, and after CFVs were inhibited, they were followed until CFVs were restored or for up to 6 hours. To determine whether CFVs could be restored by epinephrine after their abolition with FVIIai, increasing doses of epinephrine were administered to a third group of 6 animals. FVIIai abolished CFVs in 8 of 9 rabbits (P<.01). This effect was reversible, as FVIIa administration restored CFVs in all animals. Prothrombin times and activated partial thromboplastin times did not change significantly throughout the study. One single 10-minute infusion exerted complete antithrombotic effects for at least 6 hours, despite the fact that at this time point, plasma FVIIai levels were well below threshold concentrations. Epinephrine restored CFVs in 3 of 6 animals in which CFVs were inhibited by FVIIai. FVIIai exerts potent antithrombotic effects in this model; these effects were prolonged even after FVIIai was almost completely cleared from the circulation, probably as a result of the tight binding of FVIIai to TF. Thus, FVIIai might represent an antithrombotic substance of potential interest.Keywords
This publication has 11 references indexed in Scilit:
- Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.The Journal of cell biology, 1996
- Antithrombotic and Antilesion Benefits without Hemorrhagic Risks by Inhibiting Tissue Factor PathwayPathophysiology of Haemostasis and Thrombosis, 1996
- Mutational Mapping of Functional Residues in Tissue Factor: Identification of Factor VII Recognition Determinants in Both Structural Modules of the Predicted Cytokine Receptor Homology DomainBiochemistry, 1994
- Atherosclerosis: what is it and why does it occur?Heart, 1993
- Molecular and Cellular Biology of Blood CoagulationNew England Journal of Medicine, 1992
- Regulation of coagulation by a multivalent Kunitz-type inhibitorBiochemistry, 1990
- Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.Proceedings of the National Academy of Sciences, 1989
- Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA.Proceedings of the National Academy of Sciences, 1987
- Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascadeCell, 1987
- Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart DiseaseNew England Journal of Medicine, 1981